Shame it was one of the things I was awaiting news of and expected closer to the IPO listing! Great news though and this is food for thought as 40% do not respond adequately to Statins:
Statins are the standard-of-care cholesterol-lowering treatment with a global market expected to exceed US$20 billion in 2020.1 A small molecule PCSK9 inhibitor that can be combined with a statin opens the potential for a convenient and cost-effective ‘single pill’ therapy for high LDL cholesterol. The oral combination therapy is expected to have broader patient acceptance over injectable PCSK9i options that currently are available.
NYR Price at posting:
21.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)